IL6 and cancer: Among all 32 cytokines quantified, only early on-treatment fold changes of IL-6 was significantly associated with increased risk of grade ≥ 2 irAEs and both cancer-specific and all-cause mortality after multitesting adjustment (Figure 6, A and B and Supplemental Tables 10 and 11).